Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease

• Published in: Movement disorders Vol. 25; no. 15; pp. 2542 - 2549
• Main Authors: Hauser, Robert A., Schapira, Anthony H.V., Rascol, Olivier, Barone, Paolo, Mizuno, Yoshikuni, Salin, Laurence, Haaksma, Monika, Juhel, Nolwenn, Poewe, Werner
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.11.2010; Wiley; Wiley Subscription Services, Inc
• Subjects: Aged; Antiparkinson Agents - administration & dosage; Antiparkinson Agents - adverse effects; Antiparkinson Agents - therapeutic use; Benzothiazoles - administration & dosage; Benzothiazoles - adverse effects; Benzothiazoles - therapeutic use; Biological and medical sciences; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Delayed-Action Preparations - administration & dosage; Delayed-Action Preparations - adverse effects; Delayed-Action Preparations - therapeutic use; dopamine agonist; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa - therapeutic use; Male; Medical sciences; Middle Aged; Movement disorders; Neurology; Parkinson Disease - drug therapy; Parkinson's disease; Patient Satisfaction; pramipexole extended release; Quality of Life; Severity of Illness Index; treatment; Treatment Outcome; Evaluation; Nervous system diseases; Parkinson's disease; Parkinson disease; Pramipexole; Cerebral disorder; Treatment; Central nervous system disease; Dopamine agonist; pramipexole extended release; Degenerative disease; Release; Extrapyramidal syndrome

The objective of this study was to evaluate the efficacy and safety of pramipexole extended release (ER) administered once daily in early Parkinson's disease (PD). Pramipexole immediate release (IR) administered three times daily (TID) is an efficacious and generally well‐tolerated treatment fo...